{
    "clinical_study": {
        "@rank": "89198", 
        "arm_group": [
            {
                "arm_group_label": "OCTEOTRIDE", 
                "arm_group_type": "Experimental", 
                "description": "octeotride 20 mg, intramuscular injection monthly for 3 years"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (saline soluction), intramuscular injection monthly for 3 years"
            }
        ], 
        "brief_summary": {
            "textblock": "Autosomal dominant polycystic kidney disease (ADPKD) is associated with the development of a\n      variety of extrarenal manifestations of which polycystic liver disease is most common. The\n      investigators aimed to assess the changes over time of liver volume in ADPKD patients and\n      whether it is affected by the treatment with the somatostatin analogue, octreotide.\n\n      35 ADPKD patients (14 males) aged 34\u00b18 years were randomly assigned to 36 month treatment\n      with placebo (n=18) or octreotide (n=17). Clinical and liver parameters at magnetic\n      resonance (RM) were evaluated at baseline, study end and after 24 months of drug withdrawal."
        }, 
        "brief_title": "Effects of Somatostatin on Liver in ADPKD", 
        "condition": "Autosomal Dominant Polycystic Kidney Disease", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Polycystic Kidney Diseases", 
                "Polycystic Kidney, Autosomal Dominant"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  diagnosis of autosomal dominant polycystic kidney and liver disease\n\n          -  glomerular filtration rate greater than 40 ml/min\n\n        Exclusion Criteria:\n\n          -  diabetes mellitus\n\n          -  proteinuria greater than 1 g/24 hours\n\n          -  significant glomerular disease\n\n          -  urinary tract lithiasis and infections\n\n          -  symptomatic gallstones\n\n          -  biliary sludge\n\n          -  cancer\n\n          -  pregnant women\n\n          -  lactanting women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02119052", 
            "org_study_id": "ADPKD-liver"
        }, 
        "intervention": [
            {
                "arm_group_label": "OCTEOTRIDE", 
                "intervention_name": "octeotride", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Somatostatin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 18, 2014", 
        "number_of_arms": "2", 
        "official_title": "Effect of Long-acting Somatostatin on Liver in Autosomal Dominant Polycystic Kidney Disease", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Ethics Commettee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Effect of somatostatin on liver volume", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02119052"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Federico II University", 
            "investigator_full_name": "Eleonora Riccio", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Federico II University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Federico II University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}